Molecular aspects of thrombosis and antithrombotic drugs

Critical Reviews in Clinical Laboratory Sciences

Volumn 42, Issue 3, 2005, Pages 249-277

  Wu, Kenneth K ^a   Matijevic Aleksic, Nena ^b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

ADP; Aspirin; Coagulation; Direct thrombin inhibitors; Fibrin formation; GPIIbIIIa antagonists; Macrophages; Plaque instability; Platelet aggregation; Thrombin; Thromboxane; Tissue factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; ARGININE DERIVATIVE; BLOOD CLOTTING FACTOR; CLOPIDOGREL; CYCLOOXYGENASE 1; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FONDAPARINUX; HEPARIN; HIRULOG; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; RECOMBINANT HIRUDIN; SALICYLIC ACID; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TICLOPIDINE; TIROFIBAN; WARFARIN; XIMELAGATRAN; CYTOKINE; FIBRINOLYTIC AGENT;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; FIBRIN FORMATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFLAMMATION; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; LYSIS; MOLECULE; MONOCYTE; PRIORITY JOURNAL; RETROPERITONEAL HEMATOMA; REVIEW; SIDE EFFECT; SKIN NECROSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOGENICITY; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS; ANIMAL; CLINICAL PRACTICE; IMMUNOLOGY; PRACTICE GUIDELINE; THROMBOSIS;

THROMBUS;

ANIMALS; ANTICOAGULANTS; CYTOKINES; FIBRINOLYTIC AGENTS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; THROMBOSIS;

EID: 26944435240     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360590951171     Document Type: Review

References (135)

1. Wu KK. Historical Perspective. In Wu KK, Ed. Pathophysiology and Management of Thromboembolic Disorders. Pp 1-4. Littleton, Massachusetts: PSG Publishing, 1984.
2. Bizzozero J. On a new blood particle and its role in thrombosis and blood coagulation. Translated by EA Beck from the original: Virchows Arch Pathol Anat Physiol Klin Med 1882; 90: 261-332
3. Hammarsten O: Ueber das Fibrinogen. I. Die Reindarstellung des Fibrinogens. II. Die kochsalzhaltigen Losungen des Fibrinogens. Pfluegers Arch Ges Physiol 1879; 19: 563-622;
4. Hammarsten O: Pfluegers Arch Ges Physiol 1880; 22: 431-502.
5. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
6. Zucker MB, Nachmias VT. Platelet activation. Arteriosclerosis 1985; 5: 2-18.
7. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, Eds: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2nd ed. Pp 3-17. Philadelphia: JB Lippincott, 1987.
8. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
9. Voetsch B, Loscalzo J. Genetics of thrombophilia: impact on atherogenesis. Curr Opin Lipidol 2004; 15: 129-143.
10. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997; 26: 2-10.
11. Thiagarajan P, Wu KK. Mechanisms of antithrombotic drugs. Adv Pharmacol 1999; 46: 297-324.
12. Wu KK, Thiagarajan P. Endothelial cell function in hemostasis and thrombosis. Ann Rev Med 1996; 47: 315-331.
13. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
14. Dahlback B. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-488.
15. Badimon JJ, Zaman A, Helft G, Fayad Z, Fuster V Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999; 82: 997-1004.
16. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999; 353 Suppl 2: SII5-SII9.
17. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
18. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
19. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340: 115-126.
20. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
21. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-927.
22. Khan KM, Howe LR, Falcone DJ. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem 2004; 279: 22039-22046.
23. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91: 3A-6A.
24. Burke AP, Farb A, Kolodgie FD, Narula J, Virmani R. Atherosclerotic plaque morphology and coronary thrombi. J Nucl Cardiol 2002; 9: 95-103.
25. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
26. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
27. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arteriosder Thromb Vasc Biol 2000; 20: 2322-2328.
28. Miller DL, Yaron R, Yellin MJ. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 1998; 63: 373-379.
29. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
30. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203.
31. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
32. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436.
33. Bornstein P, Sage H. Structurally disctinct collagen types. Annu Rev Biochem 1980; 49: 957-1003.
34. Pareti FI, Fujimura Y, Dent JA, Holland LZ, Zimmerman TS, Ruggeri ZM. Isolation and characterization of collagen binding domain in human VWF. J Biol Chem 1986; 261: 15310-15315.
35. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
36. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102:449-461.
37. Mangin P, Nonne C, Eckly A, Ohlmann P, Freund M, Nieswandt B, Cazenave JP, Cachet C, Lanza F. A PLC gamma 2-independent platelet collagen aggregation requiring functional association of GPVI and integrin alpha2beta1. FEBS Lett 2003; 542: 53-59.
38. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12: 261-273.
39. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
40. Bauer SM. ADP receptor antagonists as antiplatelet therapeutics. Expert Opin Emerg Drugs 2003; 8: 93-101.
41. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002; 68-69: 3-58.
42. Murakami M, Kudo I. Cellular arachidonate-releasing functions of various phospholipase A2s. Adv Exp Med Biol 2003; 525: 87-92.
43. Garavito RM, Mulichak AM. The structure of mammalian cyclooxygenases. Annu Rev Biophys Biomol Struct 2003; 32: 183-206.
44. Wang LH, Kulmacz RJ. Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat 2002; 68-69: 409-422.
45. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
46. So SP, Wu J, Huang G, Huang A, Li D, Ruan KH. Identification of residues important for ligand binding of thromboxane A2 receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J Biol Chem 2003; 278: 10922-10927.
47. 2. Science 1976; 193: 1135-1137.
48. Sueda S, Kohno H, Inoue K, Fukuda H, Suzuki J, Watanabe K, Ochi N, Kawada H, Uraoka T. Intra-coronary administration of a thromboxane A2 synthase inhibitor relieves acetylcholine-induced coronary spasm. Circ J 2002; 66: 826-830.
49. Calvete JJ. Platelet integrin GPIIb/IIIa: structure-function correlations. An update and lessons from other integrins. Proc Soc Exp Biol Med 1999; 222: 29-38.
50. Naik UP, Parise LV. Structure and function of platelet alpha lib beta 3. Curr Opin Hematol 1997; 4: 317-322.
51. Fullard JF. The role of the platelet glycoprotein Ilb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 10: 1567-1576.
52. Fox JE. Transmembrane signaling across the platelet integrin glycoprotein Ub-IIIa. Ann NY Acad Sci 1994; 714: 75-87.
53. Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol Haemost Thromb 2002; 32: 216-217.
54. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42: 423-438.
55. Ahmad SS, London FS, Walsh PN. The assembly of the factor X-activating complex on activated human platelets. J Thromb Haemost 2003; 1: 48-59.
56. De Cristofaro R, De Candia E. Thrombin domains: structure, function and interaction with platelet receptors. J Thromb Thrombolysis 2003; 15: 151-163.
57. Wu KK. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J Lab Clin Med 1996; 128: 242-245.
58. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by Cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-277.
59. Wu KK. Molecular regulation and augmentation of prostacyclin biosynthesis. Agents Actions Suppl 1995; 45: 11-17.
60. Tanabe T, Ullrich V. Prostacyclin and thromboxane synthases. J Lipid Mediat Cell Signal 1995; 12: 243-255.
61. Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171-191.
62. Tsai AL, Wu KK. Structure-activity relationship between prostacyclin and its platelet receptor. Correlation of structure change and the platelet activity. Eicosanoids 1989; 2: 131-143.
63. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann NY Acad Sri 2002; 962: 122-130.
64. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-Rl2.
65. Fulton D. Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
66. Wu KK. Endothelial prostaglandin and nitric oxide synthesis in atherogenesis and thrombosis. J Formas Med Assoc 1996; 95: 661-666.
67. Salvemini D. Regulation of Cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 1997; 53: 576-582.
68. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-2290.
69. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R. Heterolo-gous cell-cell interactions: Thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).J Thromb Haemost 2003; 1: 2497-2509.
70. Willerson JT, Zoldhelyi P, Meidell R, McNatt J, Xu XM, Wu KK. Gene therapy to restore prostacyclin presence to injured endothelium. Trans Am Clin Climatol Assoc 1994; 106: 100-107.
71. Wu KK. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents Actions Suppl 1997; 48: 107-123.
72. Lin H, Lin TN, Cheung WM, Nian GM, Tseng PH, Chen SF, Chen JJ, Shyue SK, Liou JY, Wu CW, Wu KK. Cyclooxygenase-1 and bicistronic cyclooxygenase-1/ prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002; 105: 1962-1969.
73. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-204.
74. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int J Hematol 2004; 79: 103-108.
75. Dahlback B. Blood coagulation. Lancet 2000; 355: 1627-1632.
76. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
77. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-972.
78. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353.
79. Losche W, Scholz T, Temmler U, Oberle V, Claus RA. Platelet-derived microvesicles transfer tissue factor to monocytes but not to neutrophils. Platelets 2004; 15: 109-115.
80. Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997; 78: 392-395.
81. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-116.
82. Tollefsen DM. Heparin cofactor II. Adv Exp Med Biol 1997; 425: 35-44.
83. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-1214.
84. van Hinsbergh WWM. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis 1988; 18: 307-327.
85. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-4256.
86. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358-1362.
87. Chalela JA, Merino JG, Warach S. Update on stroke. Curr Opin Neural 2004; 17: 447-451.
88. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2004; 439-456.
89. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002; 113: 636-642.
90. Schambeck CM, Grossmann R, Zonnur S, Berger M, Teuchert K, Spahn A, Walter U. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004; 92: 42-46.
91. Poort SR, Rosendaal FR, Reitsma PH, Betina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
92. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 2002; 71: 285-290.
93. Folsom AR, Aleksic N, Wang L, Cushman M, Wu KK, White RH. Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioschr Thromb Vasc Biol 2002; 22: 1018-1022.
94. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614.
95. Koenen RR, Tans G, van Oerle R, Hamulyak K, Rosing J, Hackeng TM. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102: 1686-1692.
96. Salomon O, Steinberg DM, Zivelin A. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19:511-518.
97. Vane JR, Bolting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258.
98. Wu KK Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med 2003; 3: 107-112.
99. Wu KK. Control of COX-2 and iNOS gene expressions by aspirin and salicylate. Thromb Res 2003; 110:273-276.
100. Saunders MA, Sansores-Garcia L, Gilroy DW, Wu KK. Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts. J Biol Chem 2001; 276: 18897-18904.
101. Cieslik K, Zhu Y, Wu KK. Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway. J Biol Chem 2002; 277: 49304-49310.
102. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
103. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003; 3: 113-122.
104. Micieli G, Cavallini A. New therapeutic strategies with antiplatelet agents. Neural Sci 2004; 25 Suppl 1:S13-S15.
105. Bhatt DL, Topol EJ. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263-268.
106. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worleys et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention: IMPACT investigators. Circulation 1995; 91: 2151-2157.
107. PRISM-PLUS study investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q Xwave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med 1998; 338: 1488-1497.
108. Marki WE, Grossenbacher H, Grutter MG, Liersch MH, Meyhack B, Heim J. Recombinant hirudin: genetic engineering and structure analysis. Semin Thromb Hemost 1991; 17: 88-93.
109. Walenga JM, Pifarre R, Hoppensteadt DA, Farced J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Semin Thromb Hemost 1989; 15:316-333.
110. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW 2nd. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249: 277-280.
111. Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol 1991; 221: 583-601.
112. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KT., Fenton JW 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101.
113. Farced J, Hoppensteadt D, Iqbal O, Tobu M, Lewis BE. Practical issues in the development of argatroban: a perspective. Pathophysiol Haemost Thromb 2002; 32 Suppl 3: 56-65.
114. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 2002; 28 Suppl 2: 15-24.
115. Crowther MA, Weitz JI. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin Investig Drugs 2004; 13: 403-413.
116. McCullough PA, Dorrell KA, Sandberg KR, Yerkey MW. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation. Rev Cardiovasc Med 2004; 5: 99-103.
117. Chang P. New anticoagulants for venous thromboembolic disease. Drugs 2004; 7: 50-57.
118. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 Suppl 2: 24-38.
119. Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29: 170-178.
120. Prandoni P, Carnovali M, Marchiori A, Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164: 1077-1083.
121. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004; 110: c454-458.
122. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 2121-2131.
123. Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004; 9: 225-239.
124. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa. Best Pract Res Clin Haematol 2004; 17: 89-104.
125. Turpie AG, Bauer KA, Eriksson BI, Lassen MR, PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-1726.
126. Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720.
127. Bauer KA, Eriksson BI, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
128. Buller HR, Davidson BL, Decousus H, Callus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-873.
129. Shapiro S. Warfarin sodium derivative: (coumadin sodium); an intravenous hypoprothrombinemia-inducing agent. Angiology 1953; 4: 380-390.
130. Sadler JE. Medicine: K is for koagulation. Nature 2004; 427: 493-494.
131. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Noventa F, Iliceto S. Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment. Thromb Haemost 2003; 89: 760-764.
132. Nozawa T, Inoue H, Iwasa A, Okumura K, Jong-dae L, Shimizu A, Hayano M, Yano K. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 2004; 68: 29-34.
133. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-1923.
134. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-654.
135. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina O, Daley GQ. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-2644.